Nurture Study reveals new and positive data showing benefits of treating pre-symptomatic infants with Spinraza at the annual congress of the World Muscle Society.
“The NURTURE study results demonstrate that early diagnosis and treatment with SPINRAZA has the potential to dramatically change the course of SMA,” said Wildon Farwell, M.D., senior medical director, clinical development at Biogen. “This is the longest available span of data on infants with SMA who began treatment in a presymptomatic period and indicates that children treated early with SPINRAZA can achieve motor milestones they would likely not attain without treatment.”
To read the full press release from Biogen click here.
